Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461586 | 0.91 | ABL1 (0.58) | HTR7HTR6ALDH1A1ADORA2BRXFP1 | |
| SCHEMBL4471688 | 0.88 | HTR7 (0.55) | HTR7HTR6ALDH1A1ADORA2BSMN1; SMN2 | |
| SCHEMBL4462921 | 0.87 | PDE1A (0.60) | HTR7HTR6ALDH1A1SMN1; SMN2ABL1 | |
| SCHEMBL1810048 | 0.82 | HTR7 (0.84) | HTR7HTR6ALDH1A1ADORA2BSMN1; SMN2 | |
| SCHEMBL4461767 | 0.82 | ADORA2B (0.73) | HTR7HTR6ALDH1A1ADORA2BSMN1; SMN2 | |
| SCHEMBL458792 | 0.80 | HTR7 (0.63) | HTR7HTR6ALDH1A1ADORA2BSMN1; SMN2 | |
| SCHEMBL29375465 | 0.80 | HTR7 (0.63) | HTR7HTR6ALDH1A1ADORA2BSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2290149 | 0.79 | HTR7 (0.65) | HTR7HTR6ALDH1A1ADORA2BSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL12804036 | 0.79 | HTR7 (0.62) | HTR7HTR6ALDH1A1ADORA2BSMN1; SMN2 | |
| SCHEMBL4471843 | 0.79 | PDE1A (0.52) | ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625919-B2 | 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | claimed |
| US-20060281761-A1 | 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-12-14 | — | — | US | claimed |
| US-20050131005-A1 | 4-azasteroid derivatives as androgen receptor modulators | WANG JIABING (US) | 2005-06-16 | — | — | US | claimed |
| EP-1501512-A2 | 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | claimed |
| WO-2003092588-A2 | 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-11-13 | — | — | WO | claimed |
| US-7625919-B2 | 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7550468-B2 | Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase | CHEN ING-JUN | 2009-06-23 | — | — | US | disclosed |
| US-20060281761-A1 | 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-12-14 | — | — | US | disclosed |
| US-20050209242-A1 | Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase | CHEN ING-JUN | 2005-09-22 | — | — | US | disclosed |
| US-20050131005-A1 | 4-azasteroid derivatives as androgen receptor modulators | WANG JIABING (US) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281761-A1 | 4-azasteroid derivatives as androgen receptor modulators | NR5A1, AR, NR3C1 | HTR7 2575/4885HTR6 3445/4885ALDH1A1 1068/4885 |
| US-20050131005-A1 | 4-azasteroid derivatives as androgen receptor modulators | AR, NR5A1, NR3C1 | HTR7 2618/4885HTR6 3477/4885ALDH1A1 1093/4885 |
| US-20050209242-A1 | Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase | PDE3A, PDE5A, PDE3B | HTR7 120/4885HTR6 510/4885ALDH1A1 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.